Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer with a KRAS G12C mutation.
- Your cancer is advanced or has spread, and cannot be cured with surgery or radiation alone.
- You have at least one tumor that can be measured on a scan.
- You have not had any prior cancer treatment for advanced or metastatic disease.
- You may have brain metastases if they are small (≤20mm) and not causing symptoms or needing immediate treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.